The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

Novartis CEO Vas Narasimhan weighs in on the impact of the new U.S. administration and artificial intelligence on the ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...

The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...

Q4 2024 Management View CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and ...

Swiss pharmaceutical giant Novartis on Friday reported fourth-quarter results after repeatedly raising its full-year guidance ...

Novartis AG said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug, ...

Shares of Swiss pharmaceutical giant Novartis AG were flat on Friday morning in heavy trading volume, despite the company ...